Physician profile
Van Meeks
NPI 1255574984
$6,013.48
in general payments reported to CMS, 2019-2025
45 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $996 · 2021: $511 · 2022: $858 · 2023: $832 · 2024: $1,386 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,128.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $744.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $400.03 | 2021-2025 | |
| Pfizer INC. | $359.01 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.64 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $325.93 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.63 | 2019-2024 | Xifaxan |
| Amgen INC. | $234.02 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbott Laboratories | $166.43 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $149.14 | 2019-2024 | Airsupra, Farxiga |
| Supernus Pharmaceuticals, INC. | $132.37 | 2019-2022 | Tlando, Xyosted |
| Ironshore Pharmaceuticals INC. | $132.34 | 2019 | |
| Corium, LLC | $130.42 | 2022-2024 | Azstarys |
| Astellas Pharma US INC | $117.29 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $102.59 | 2019-2023 | Xarelto |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Meeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.